PT  - JOURNAL ARTICLE
AU  - Manko, Christopher D.
AU  - Ahmed, Mohamed S.
AU  - Harrison, Lavinia H.
AU  - Kodavatiganti, Sree
AU  - Lugo, Noelia
AU  - Konadu, Jason O.
AU  - Khan, Farrin
AU  - Massari, Carrie A.
AU  - Sealey, Tenisha K.
AU  - Addison, Maame Efua
AU  - Mbah, Celine N.
AU  - McCall, Kenneth L.
AU  - Fraiman, Joseph B.
AU  - Piper, Brian J.
TI  - National Increase but Pronounced Regional Disparities in Naloxone Prescribing to United States Medicaid and Medicare Patients
AID  - 10.1101/2023.05.17.23290119
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.05.17.23290119
4099  - http://medrxiv.org/content/early/2023/05/24/2023.05.17.23290119.short
4100  - http://medrxiv.org/content/early/2023/05/24/2023.05.17.23290119.full
AB  - Background Opioid overdoses in the US have increased to unprecedented levels. Administration of the opioid antagonist naloxone can prevent overdoses. This study was conducted to reveal the pharmacoepidemiologic patterns in naloxone prescribing to Medicaid patients from 2018-2021 as well as Medicare in 2019.Methods The Medicaid State Drug Utilization Data File was utilized to extract information on number of prescriptions and amount prescribed of naloxone at a national and state level. States with naloxone prescription rates differing from the mean by ≥ 1.96 standard deviations were considered statistically significant. The Medicare Provider Utilization and Payment was also utilized to analyze prescription data from 2019.Results The number of generic naloxone prescriptions per 100,000 Medicaid enrollees decreased 5.15% whereas brand naloxone prescriptions increased 245.00% from 2018-2021. There was a 33.14-fold difference in prescriptions between the highest (New Mexico = 1809.55) and lowest (South Dakota = 54.61) states in 2019. Medicare saw a 30.32-fold difference in prescriptions between the highest (New Mexico) and lowest states (also South Dakota) after correcting per 100,000 enrollees.Conclusions This pronounced increase in the number of naloxone prescriptions to Medicaid patients from 2018-2021 indicates a national response to this widespread public health emergency. Further research into the origins of the pronounced state-level disparities is warranted.Competing Interest StatementBrian J. Piper was (2019-21) part of an osteoarthritis research team supported by Pfizer and Eli Lilly. The other authors have no disclosures.Funding StatementThis research was generously supported by the Health Resources and Services Administration (D34HP31025).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study used enrollee and prescription data that is publicly available since the start of data collection.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors. https://www.medicaid.gov/medicaid/prescription-drugs/state-drug-utilization-data/index.html https://www.medicaid.gov/medicaid/national-medicaid-chip-program-information/medicaid-chip-enrollment-data/medicaid-enrollment-data-collected-through-mbes/index.html https://data.cms.gov/provider-summary-by-type-of-service/medicare-part-d-prescribers https://www.kff.org/medicare/state-indicator/total-medicare-beneficiaries/?currentTimeframe=0&sortModel=%7B%22colId%22:%22Location%22,%22sort%22:%22asc%22%7D